Probiotics in inflammatory bowel disease: microbial modulation and therapeutic prospects.
Study Design
- Tipo di studio
- Review
- Popolazione
- review of probiotics as therapeutic strategy for inflammatory bowel disease
- Intervento
- Probiotics in inflammatory bowel disease: microbial modulation and therapeutic prospects. None
- Comparatore
- None
- Esito primario
- None
- Direzione dell'effetto
- Positive
- Rischio di bias
- Unclear
Abstract
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder that represents a significant public health challenge worldwide. This multifactorial condition results from complex interactions among genetic, environmental, immune, and microbial factors. Some beneficial microbes, known as probiotics, have been identified as promising therapeutic agents for inflammatory conditions, such as IBD. In this review, we explore the potential of probiotics as a therapeutic strategy for managing IBD. Probiotics have shown promise due to their ability to modulate the gut microbiota, regulate histamine levels, and enhance vitamin D metabolism, thereby promoting a tolerant immune profile and reducing inflammation. While the exact mechanisms underlying these benefits remain incompletely understood, probiotics represent a novel and emerging approach for alleviating the exacerbated inflammation characteristic of this disorder.
TL;DR
The potential of probiotics as a therapeutic strategy for managing IBD is explored, demonstrating their ability to modulate the gut microbiota, regulate histamine levels, and enhance vitamin D metabolism, thereby promoting a tolerant immune profile and reducing inflammation.
Used In Evidence Reviews
Similar Papers
Journal of inflammation research · 2014
Vitamin D and inflammatory diseases.
Gastroenterology · 2017
Diet as a Trigger or Therapy for Inflammatory Bowel Diseases.
The journal of headache and pain · 2020
Gut-brain Axis and migraine headache: a comprehensive review.
Joint bone spine · 2010
Vitamin D and inflammation.
The Australian and New Zealand journal of psychiatry · 2017
A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression.
World journal of gastroenterology · 2016